Tiziana Life Sciences Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLSA research report →
About the company
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression.
- CEO
- Ivor R. Elrifi
- IPO
- 2018
- Employees
- 9
- HQ
- London, GB
Price Chart
- Market Cap
- $83.35M
- P/E
- -4.11
- P/S
- 0.00
- P/B
- 2.33
- EV/EBITDA
- 2.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -125.84%
- ROIC
- -41.20%
- Revenue
- $0 · 0.00%
- Net Income
- $-18,431,000 · -55.37%
- EPS
- $-0.32 · -45.45%
- Op Income
- $-21,132,000
- FCF YoY
- -942.29%
- 52W High
- $2.60
- 52W Low
- $1.04
- 50D MA
- $1.31
- 200D MA
- $1.53
- Beta
- 0.42
- Avg Volume
- 207.51K
Get TickerSpark's AI analysis on TLSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 12, 26 | CERRONE GABRIELE M | other | 15,000 |
| Mar 18, 26 | Shah Keeren Rameshchandra | other | 0 |
| May 6, 24 | Shah Keeren Rameshchandra | other | 15,625 |
| Mar 14, 27 | Shah Keeren Rameshchandra | other | 46,875 |
| Mar 13, 27 | Shah Keeren Rameshchandra | other | 83,333 |
| Apr 3, 26 | Shah Keeren Rameshchandra | other | 125,000 |
| Sep 4, 29 | Shah Keeren Rameshchandra | other | 12,500 |
| Mar 18, 26 | CERRONE GABRIELE M | other | 0 |
| Mar 18, 26 | CERRONE GABRIELE M | other | 1,629,702 |
| May 3, 28 | CERRONE GABRIELE M | other | 250,000 |
Our TLSA coverage
Recent articles, reports, and earnings notes.
No research on TLSA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TLSA report →Similar companies
Peers in the same neighborhood.